News

2008
August – Teuchner B, Schmid E, Ulmer H, Gottardi W, Nagl M. Tolerability of N-chlorotaurine plus ammonium chloride in the rabbit and human eye – a phase 1 clinical study. Graefes Arch Clin Exp Ophthalmol 2008.
May – Huber J, Winter P, Gottardi W, Scholl-Burgi S, Prokop W, Nagl M. Tolerability of N-chlorotaurine in the bovine mammary gland. Journal of Dairy Research 2008; 75: 248-256.
February – OPKO Health & Pathogenics Announce Data Publication Demonstrating the Potential Utility of NCT in a Severe Eye Infection

2007
May – N-Chlorotaurine and ammonium chloride: An antiseptic preparation with strong bactericidal activity. Int. J. Pharmaceut.2007; 335: 32-40.

2006
August – Acuity Pharmaceuticals & Pathogenics Announce Preclinical Data Demonstrating Utility of NCT in Viral Conjunctivitis
May – N-Chlorotuarine is an Effective Antiviral Agent against Adenovirius In Vitro and in the Ad5/NZW Rabbit Ocular Model. Invest Ophth Vis Sci. 2006; 47: 2021-2026 (successful animal trial of efficacy in eyes)
April – Pathogenics, Inc. Licenses Worldwide Rights To Novel Anti-infective Compound for Ophthalmological Use
March – Protein Sites of attack of N-Chlorotaurine in Escheria coli. Proteomics 2006; 6, 865-869 (proteomic investigation of mechanism of action)
March – A novel N-chlorotaurine-corticosteroid combination as a preservative-free local disinfectant: Influence on the ciliary beat frequency in vitro. Acta Oto-Laryngologica 2006; 126: 291-294 (successful pre-clinical study of safety in nasal mucus)

2005
July – Tolerability of N-chlorotaurine in chronic rhinosinusitis applied via yamik catheter. Auris Nasus Larynx 2005; 32: 359-364 (successful human clinical trial of safety and tolerability in sinuses)
April - Tolerability and efficacy of N-chlorotaurine in epidemic keratoconjunctivitis – a double-blind randomized phase 2 clinical trial. J Ocular Pharmacol Ther 2005; 21: 157–165 (successful human clinical trial of efficacy in eyes)
February – Tyrol Therapeutics, LLC (formerly Pathogenics, LLC) merges with Pathogenics, Inc. (formerly Needle Impulse, Corp.)

2004
May – Acute Otitis Externa: Efficacy and Tolerability of N-Chlorotaurine, a Novel Endogenous Antiseptic Agent. Laryngoscope 2004; 114: 850-854 (successful human clinical trial of efficacy in outer ear)
January - Tolerability of N-chlorotaurine in the guinea pig middle ear - a pilot study using an improved application system. Ann Otol Rhino Larygol 2004; 113: 76-81 (successful animal trial of efficacy in middle ear)

2003
May – In vitro study on the influence of N-chlorotaurine on the ciliary beat frequency of nasal mucosa. Am J Rhinol 2003; 17: 149-152 (successful pre-clinical study of safety in nasal mucus)
January - Tolerability and efficacy of N-chlorotaurine compared to chloramine T for treatment of chronic leg ulcers with purulent coating. British Journal of Dermatology 2003; 149: 590-597 (successful human clinical trial of efficacy in leg ulcers)

2002
December – Pathogenics, LLC is assigned the exclusive patent license for N-Chlorotaurine from Atlantic Technology Ventures, Inc. and its inventors
November - Pathogenics, LLC incorporated